Definition of LLDAS: "A state assc w/low likelihood of adverse outcome, considering disease activity and medication safety; it must be favorable, deployable, feasible, and attainable," - Dr. E Morand #EULAR2021 @RheumNow https://t.co/oMMU3AjhmX

Dr. G Robinson Abstr#OP0013 on sex link b/t autoimmune & CV risk 👉Hormones drive funx change in Treg transciptome 👉anti-inflamm Tregs⬆️in males 👉Tregs are more suppressive in males 👉Treg transciptome profile altered b/t males & females in autoimmunity #EULAR2021 @rheumnow https://t.co/p4Awfu2hiK

Plenary abstract #OP0013. In autoimmunity: Male lipoprotein profile: ^ CV risk, but had ^ anti-inflammatory features vs females, 2/2 sex hormones. Possible pathway to dx and tx of inflammatory disease in the future? #EULAR2021 @RheumNow @eular_org https://t.co/Z2KmEQftve

• https://ard.bmj.com/content/80/Suppl_1/8.1.full

Prof A Doria introduces SLE-DAS, a new instrument to measure Lupus activity that is continuous and highly sensitive to changes in dz activity #EULAR2021 @rheumnow Watch the oral presentation 6/4/21 Abst#OP0297 https://t.co/gE9QhLL1oj

What is your treat to target for lupus patients? #EULAR2021 @rheumnow

"50% of time spent in LLDAS = 50% less damage accrual"- Prof E Morand reviews data on low disease activity state in lupus https://t.co/FU3hPvuyRU

Prof Van Vollenhoven reveals the Definition of Remission in SLE (DORIS 2021): treating SLE to target #EULAR2021 @rheumnow 👉SLEDAI=0 👉MD global<0.5 👉dsDNA, C3/C4 does not matter 👉prednisone <=5 mg/d, stable meds 👉remission can be met at any point (duration not required https://t.co/TwusJkXR19